Lupin is currently trading at Rs. 2245.00, up by 2.70 points or 0.12% from its previous closing of Rs. 2245.10 on the BSE.

The scrip opened at Rs. 2256.30 and has touched a high and low of Rs. 2259.85 and Rs. 2235.10 respectively. So far 7895 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2261.95 on 17-Feb-2026 and a 52 week low of Rs. 1774.00 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 2259.85 and Rs. 2204.85 respectively. The current market cap of the company is Rs. 102485.09 crore.

The promoters holding in the company stood at 46.89%, while Institutions and Non-Institutions held 47.07% and 6.03% respectively.

Lupin has received the approval from European Commission for its biosimilar ranibizumab, Ranluspec (for vials and pre-filled syringes), following the recent positive opinion from the Committee for Medicinal Products for Human Use.

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A. Its indications encompass the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, proliferative diabetic retinopathy, and choroidal neovascularization.

Lupin’s biosimilar ranibizumab will be commercialized by Sandoz across the European Union (excluding Germany). In France, the product will be commercialized by two companies, Sandoz and Biogaran.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.